drugset / Trial / NCT03946462

Nitric Oxide During CPB to Reduce AKI in Neonates

NCT03946462

RandomizedParallel-groupDouble-blindTreatment

Summary

This is a prospective, randomized, double-blind, placebo-controlled pilot study to investigate whether supplemental Nitric Oxide (NO) gas delivered during cardiac surgery with cardiopulmonary bypass (CPB) reduces the incidence and impact of acute kidney injury (AKI) in neonates undergoing surgery for congenital heart disease (CHD), when compared to placebo gas

Timeline

Start
2021-10
Primary completion
2022-10
Completion
2023-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Nitric Oxide Other / unclassified 20 ppm Other